X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs IPCA LABS - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA IPCA LABS SUN PHARMA/
IPCA LABS
 
P/E (TTM) x 25.7 38.8 66.2% View Chart
P/BV x 3.8 3.0 126.2% View Chart
Dividend Yield % 0.6 0.2 354.5%  

Financials

 SUN PHARMA   IPCA LABS
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
IPCA LABS
Mar-17
SUN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs842643 131.0%   
Low Rs572503 113.8%   
Sales per share (Unadj.) Rs131.6254.4 51.7%  
Earnings per share (Unadj.) Rs32.716.1 203.5%  
Cash flow per share (Unadj.) Rs38.029.8 127.5%  
Dividends per share (Unadj.) Rs3.501.00 350.0%  
Dividend yield (eoy) %0.50.2 283.5%  
Book value per share (Unadj.) Rs152.7194.6 78.5%  
Shares outstanding (eoy) m2,399.26126.20 1,901.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.42.3 238.6%   
Avg P/E ratio x21.635.7 60.7%  
P/CF ratio (eoy) x18.619.2 96.8%  
Price / Book Value ratio x4.62.9 157.3%  
Dividend payout %10.76.2 172.0%   
Avg Mkt Cap Rs m1,696,87772,300 2,347.0%   
No. of employees `00017.513.3 131.7%   
Total wages/salary Rs m49,0236,960 704.4%   
Avg. sales/employee Rs Th18,028.32,413.5 747.0%   
Avg. wages/employee Rs Th2,798.8523.2 535.0%   
Avg. net profit/employee Rs Th4,479.5152.4 2,938.4%   
INCOME DATA
Net Sales Rs m315,78432,106 983.6%  
Other income Rs m6,232226 2,761.0%   
Total revenues Rs m322,01632,332 996.0%   
Gross profit Rs m100,8934,448 2,268.4%  
Depreciation Rs m12,6481,730 731.3%   
Interest Rs m3,998241 1,660.3%   
Profit before tax Rs m90,4792,703 3,347.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,116675 1,794.4%   
Profit after tax Rs m78,4622,028 3,868.9%  
Gross profit margin %31.913.9 230.6%  
Effective tax rate %13.425.0 53.6%   
Net profit margin %24.86.3 393.4%  
BALANCE SHEET DATA
Current assets Rs m329,53717,340 1,900.5%   
Current liabilities Rs m178,8709,559 1,871.2%   
Net working cap to sales %47.724.2 196.9%  
Current ratio x1.81.8 101.6%  
Inventory Days Days79100 78.7%  
Debtors Days Days8357 146.4%  
Net fixed assets Rs m204,76620,779 985.4%   
Share capital Rs m2,399252 950.6%   
"Free" reserves Rs m363,99724,499 1,485.8%   
Net worth Rs m366,39724,553 1,492.3%   
Long term debt Rs m14,3613,517 408.3%   
Total assets Rs m614,10239,595 1,551.0%  
Interest coverage x23.612.2 193.3%   
Debt to equity ratio x00.1 27.4%  
Sales to assets ratio x0.50.8 63.4%   
Return on assets %13.45.7 234.3%  
Return on equity %21.48.3 259.3%  
Return on capital %24.810.5 236.8%  
Exports to sales %048.6 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs mNA4,571 0.0%   
Fx inflow Rs m44,11815,617 282.5%   
Fx outflow Rs m24,4845,828 420.1%   
Net fx Rs m19,6349,790 200.6%   
CASH FLOW
From Operations Rs m70,8222,764 2,562.1%  
From Investments Rs m-42,216-1,432 2,948.7%  
From Financial Activity Rs m-22,854-1,591 1,436.2%  
Net Cashflow Rs m6,107-259 -2,359.6%  

Share Holding

Indian Promoters % 63.7 45.9 138.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 11.4 45.0%  
FIIs % 23.0 25.3 90.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 17.4 47.7%  
Shareholders   133,026 36,892 360.6%  
Pledged promoter(s) holding % 0.5 2.1 24.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   FULFORD INDIA  VENUS REMEDIES  PIRAMAL ENTERPRISES  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Market at Record Highs; Strong ITC & RIL Performance & Other Top Cues to Sway the Market Today(Pre-Open)

Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services. At the closing bell last week.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS